Iconovo
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more
Iconovo (ICO) - Total Liabilities
Latest total liabilities as of December 2025: Skr13.16 Million SEK
Based on the latest financial reports, Iconovo (ICO) has total liabilities worth Skr13.16 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Iconovo - Total Liabilities Trend (2015–2025)
This chart illustrates how Iconovo's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Iconovo Competitors by Total Liabilities
The table below lists competitors of Iconovo ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tira Austenite Tbk
JK:TIRA
|
Indonesia | Rp227.30 Billion |
|
Rubicon Technology Inc
PINK:RBCN
|
USA | $677.00K |
|
Kanger International Bhd
KLSE:0170
|
Malaysia | RM33.40 Million |
|
Biofish Holding AS
OL:BFISH
|
Norway | Nkr84.95 Million |
|
Mountain Valley MD Holdings Inc
OTCQB:MVMDF
|
USA | $81.00K |
|
IBC Advanced Alloys Corp
OTCQB:IAALF
|
USA | $19.15 Million |
|
Melewar Industrial Group Bhd
KLSE:3778
|
Malaysia | RM181.72 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Iconovo's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Iconovo's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Iconovo (2015–2025)
The table below shows the annual total liabilities of Iconovo from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr13.16 Million | -20.10% |
| 2024-12-31 | Skr16.47 Million | +13.19% |
| 2023-12-31 | Skr14.55 Million | -54.48% |
| 2022-12-31 | Skr31.97 Million | +177.80% |
| 2021-12-31 | Skr11.51 Million | +38.41% |
| 2020-12-31 | Skr8.32 Million | +67.69% |
| 2019-12-31 | Skr4.96 Million | -43.11% |
| 2018-12-31 | Skr8.72 Million | -17.57% |
| 2017-12-31 | Skr10.57 Million | -7.06% |
| 2016-12-31 | Skr11.38 Million | +118.88% |
| 2015-12-31 | Skr5.20 Million | -- |